Marcus Capital LLC Lowers Position in Edwards Lifesciences Corporation (EW)

Marcus Capital LLC lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 22.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,725 shares of the medical research company’s stock after selling 5,125 shares during the quarter. Edwards Lifesciences Corporation comprises about 1.8% of Marcus Capital LLC’s holdings, making the stock its 25th largest position. Marcus Capital LLC’s holdings in Edwards Lifesciences Corporation were worth $2,096,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Bbva Compass Bancshares Inc. grew its holdings in shares of Edwards Lifesciences Corporation by 29.5% during the first quarter. Bbva Compass Bancshares Inc. now owns 2,768 shares of the medical research company’s stock worth $260,000 after buying an additional 631 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences Corporation by 10.2% in the 1st quarter. Bank of New York Mellon Corp now owns 2,026,810 shares of the medical research company’s stock valued at $190,663,000 after purchasing an additional 187,122 shares in the last quarter. Suntrust Banks Inc. boosted its holdings in Edwards Lifesciences Corporation by 2.6% in the 1st quarter. Suntrust Banks Inc. now owns 26,208 shares of the medical research company’s stock valued at $2,463,000 after purchasing an additional 675 shares in the last quarter. Financial Engines Advisors L.L.C. boosted its holdings in Edwards Lifesciences Corporation by 14.9% in the 1st quarter. Financial Engines Advisors L.L.C. now owns 38,754 shares of the medical research company’s stock valued at $3,646,000 after purchasing an additional 5,028 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its holdings in Edwards Lifesciences Corporation by 203.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 133,806 shares of the medical research company’s stock valued at $12,587,000 after purchasing an additional 89,668 shares in the last quarter. 82.36% of the stock is currently owned by hedge funds and other institutional investors.

EW has been the topic of a number of analyst reports. Vetr lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 price objective on the stock. in a report on Monday, May 15th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 price objective on the stock in a report on Monday, May 22nd. Goldman Sachs Group, Inc. (The) initiated coverage on Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a report on Monday, August 28th. Finally, Barclays PLC lifted their price objective on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a report on Thursday, July 27th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $120.75.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,600 shares of the stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total value of $656,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,641 shares of company stock valued at $15,013,114. 2.13% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/10/marcus-capital-llc-lowers-position-in-edwards-lifesciences-corporation-ew.html.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded up 0.76% on Friday, hitting $113.19. The company had a trading volume of 1,612,089 shares. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75. The stock has a market cap of $23.90 billion, a PE ratio of 34.33 and a beta of 0.64. The company has a 50-day moving average of $114.46 and a 200 day moving average of $108.19.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. The business had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.76 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply